GlassScriptPhysician profile
Amy J Zuber
NPI 1477558914
$2,110.43
in general payments reported to CMS, 2019-2025
22 companies · $42.99 in 2025
The $42.99 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,660 · 2020: $332 · 2022: $32.20 · 2023: $42.98 · 2025: $42.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $85.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $85.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $292.08 | 2019-2020 | |
| Novo Nordisk INC | $236.47 | 2019-2022 | |
| Amgen INC. | $216.87 | 2019-2022 | |
| Lilly USA, LLC | $199.79 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $158.17 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.09 | 2019-2020 | |
| Allergan, INC. | $109.25 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $103.84 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $96.15 | 2019 | |
| Abbvie INC. | $81.79 | 2019-2023 | Ubrelvy, Synthroid |
| Stimwave Technologies Incorporated | $70.15 | 2019 | |
| Amarin Pharma, INC. | $64.52 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $60.96 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $58.08 | 2019-2020 | |
| Pfizer INC. | $56.93 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $46.34 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Arbor Pharmaceuticals, INC. | $28.72 | 2019 | |
| Astellas Pharma US INC | $23.95 | 2019 | |
| Exact Sciences Corporation | $20.60 | 2025 | The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $17.80 | 2019 | |
| Glaxosmithkline, LLC. | $16.68 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Zuber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.